NCT02333162View on ClinicalTrials.gov

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 5, 2014

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions
Previously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Acute Myeloid LeukemiaRecurrent Hematologic Malignancy
Interventions
DRUG

Fludarabine Phosphate

Given IV

DRUG

Melphalan

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMTMI

RADIATION

Total Marrow Irradiation

Undergo IMTMI

PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic PBSCT

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo allogeneic PBSCT

PROCEDURE

Allogeneic Bone Marrow Transplantation

Undergo allogeneic BMT

DRUG

Tacrolimus

Given IV or PO

DRUG

Mycophenolate Mofetil

Given IV or PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER